Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. - Wikidata - awgldk - TriplyDB

Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.

Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.

http://www.wikidata.org/entity/Q53214416

about

Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation ¹⁸F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE).Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization.Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer.Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma.Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma.Antiangiogenic therapies for advanced hepatocellular carcinoma.Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.Positron emission tomography in malignancies of the liver, pancreas and biliary tract - indications and potential pitfalls.Biomarker studies on radiotherapy to hepatocellular carcinoma.Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma.Uncommon extrahepatic metastases from hepatocellular carcinoma.Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma.Multiparametric human hepatocellular carcinoma characterization and therapy response evaluation by hyperpolarized (13) C MRSI.Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research.Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?Treatment strategies for advanced hepatocellular carcinoma: Sorafenib hepatic arterial infusion chemotherapy

P2860

Q26783895-208CB218-316E-43CE-9147-AE960CDF8FEA Q26784218-BAAC6F03-4B62-40B4-AFCF-955BD601E31D Q27005824-268685D6-AA70-4E8D-A4B4-AD0F6E84B5FB Q28073654-D9170C53-3350-428C-A147-F92810C11E96 Q28687190-1395E732-4D65-4FF2-8CFF-209F081FD75B Q33594891-9951B6EC-FBB0-4F21-B5F9-CF67A256A05A Q33686817-D19BCA26-F9E6-4A6F-B4C2-2FE78CB83AD7 Q34083775-9B627B36-C48D-4B33-9632-7220E92441B1 Q35626234-9F3AF19E-1240-4623-AEC0-5B8CE97ED73F Q36185594-F3EC1052-B6ED-4B38-805A-5E156E7A5B91 Q36500323-46A6DACA-FED1-4944-BC7D-89252E71E93D Q36557906-32E6234B-B3DF-4F76-B1FE-2BF4020D1C3C Q36758735-AB7C7BCF-8B4B-4E0A-9DAB-4D588BE81181 Q36804518-6DCA6B0F-6C2B-487A-8DB7-B2259C4ABA46 Q37088265-55688771-CC05-44CD-9504-A2907D8DB5D2 Q37522674-A5235F72-0899-4C72-A970-C194826C147F Q38059510-AB41C152-2B7D-475C-9C78-EA3A2DF7C4F8 Q38083433-B690168D-95B9-4F1F-8AC7-8A41D2BD9395 Q45275265-CB66AAE9-4128-4CE4-8AAE-AE915E8462A6 Q46775794-A08284BE-ACF0-4460-B3B9-5902B7B3EE93 Q48125580-A524EB69-CBAB-4BCC-A489-7028A5539D8B Q49477746-375EBC16-113E-40C7-9C29-06DDF086092D Q51326114-00CCA137-B0E7-47B5-BF99-564C75C18975 Q52661700-6B6DB8B7-DC9E-441C-AD9A-DE07C180433D Q57067866-EED2AFF2-1156-4925-929B-E8A5A0C6AD2C Q57491231-AEF4647C-AC71-4C52-B118-E8FF999A6748

P2860

Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.

http://www.wikidata.org/entity/Q53214416

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Prognostic value of 18F-FDG PE ...... tients treated with sorafenib.

@en

Prognostic value of 18F-FDG PE ...... tients treated with sorafenib.

@nl

type

label

Prognostic value of 18F-FDG PE ...... tients treated with sorafenib.

@en

Prognostic value of 18F-FDG PE ...... tients treated with sorafenib.

@nl

prefLabel

Prognostic value of 18F-FDG PE ...... tients treated with sorafenib.

@en

Prognostic value of 18F-FDG PE ...... tients treated with sorafenib.

@nl

P1433

Q53214416-379D7592-FC05-4FFE-A826-211168719774

P1476

Q53214416-2C075295-630F-40E4-AA86-A9168FE196DB

P2093

Q53214416-0D6DE983-17FA-462F-9505-454CDCEB1484

Q53214416-275018FB-BC96-4A15-8002-7CBBF6D13729

Q53214416-3F089835-7BAB-4F8F-81EE-5D28D72ED6F3

Q53214416-6630F728-9217-4E21-BB7A-80817306A93C

P2860

Q53214416-14A0A803-289E-409A-A81A-E792CCBDB6EA

Q53214416-15DE36D6-27EF-4B49-93B1-3425E91E50A2

Q53214416-4EFDC94B-022C-450D-AC93-8E5F4562680E

Q53214416-6A90E049-D0A2-4018-AB9E-00324C6801EE

Q53214416-97AE9D8D-4784-4879-AEAD-72C950667F30

Q53214416-9961C985-AA8D-4339-B073-3E39E6C61DEA

Q53214416-A6EF8AC0-370F-4AC9-A027-1B47675A4C6B

Q53214416-B01C6228-86FB-45DE-91F9-6EC651B5D95D

Q53214416-BF0F047D-D36A-4EBA-8401-2FE3FE22720A

Q53214416-EB101C63-BF94-478F-9C75-DDF9EB99F75C

P304

Q53214416-C6014F2B-1026-4ACF-8826-3437B8749A25

P31

Q53214416-E2B70437-9B22-4F63-A958-A170D0B7265A

P356

Q53214416-30A867B8-7EC4-4931-B611-14D0B28FB105

P433

Q53214416-3FAA4E54-9CF7-47F0-ACAD-40500D10C48D

P478

Q53214416-36B382B1-8B8F-4D05-B8B5-4B9601E872CC

P50

Q53214416-17ADE404-6842-4F27-9736-2C23065BF33A

Q53214416-8DCD9160-2733-454C-B2CF-BA173E44B5DE

Q53214416-BB2CE3B5-B432-4AAB-A995-6B7522FFB5E1

Q53214416-EAADF116-E32B-4A10-94B8-6AA686FEC45E

P577

Q53214416-E6FA74D2-F944-4C7D-8B21-DBCC6C54666C

P698

Q53214416-4BE33043-16EA-4BDE-8DE4-6B1D74952281

P356

J.1478-3231.2011.02541.X

P1433

Liver International

P1476

Prognostic value of 18F-FDG PE ...... atients treated with sorafenib

@en

P2093

Do Young Kim

http://www.w3.org/2001/XMLSchema#string

Hyo Jung Seo

http://www.w3.org/2001/XMLSchema#string

Jae Hoon Lee

http://www.w3.org/2001/XMLSchema#string

Jong Doo Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Sorafenib in advanced hepatocellular carcinoma

Hepatocellular carcinoma

Management of hepatocellular carcinoma

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.

Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma.

P304

1144-1149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1478-3231.2011.02541.X

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21745288

http://www.w3.org/2001/XMLSchema#string